New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
09:07 EDTMTG, HD, CSX, NVO, RDN, BBRY, CZR, LCC, AAPL, CELG, TSLAOn The Fly: Pre-market Movers
HIGHER: US Airways (LCC), up 2% after WSJ says U.S. would likely clear a merger with AMR(AAMRQ)... CSX (CSX), up 1.6% following positive Barron's mention... Celgene (CELG), up 1.6% after Pomalyst approved by FDA, Revlimid approved by China SFDA... DOWN AFTER EARNINGS: Radian Group (RDN), down 8%. MGIC Investment (MTG), down 3.6% in sympathy... ALSO LOWER: Novo Nordisk (NVO), down 13.5% following FDA Complete Response Letter for Tresiba and Ryzodeg... Caesar's Entertainment (CZR), down 7.6% following double-digit percentage gains Thursday and Friday... Blackberry (BBRY), down 3.2% after report says Home Depot (HD) replacing BB phones with Apple (AAPL) iPhones... Tesla (TSLA), down 2.7% ahead of upcoming earnings report, following critical review of Model S in NY Times.
News For LCC;NVO;TSLA;CZR;CSX;CELG;BBRY;HD;AAPL;RDN;MTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
December 9, 2014
07:37 EDTTSLAUBS to hold a conference
Subscribe for More Information
07:35 EDTTSLATesla Motors volatility flat as shares trend lower
Tesla Motors December weekly call option implied volatility is at 48, December is at 42, January is at 39; compared to its 26-week average of 46 according to Track Data, suggesting non-directional price movement.
06:20 EDTAAPLJudge denies Apple's efforts to throw out iPod pricing suit, WSJ reports
Subscribe for More Information
05:46 EDTCELGCelgene presents POMALYST/IMNOVID Phase IIIb study results at ASH meeting
Celgene announced that results from the STRATUS trial, a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting. Pomalidomide is marketed as POMALYST in the United States and IMNOVID in the European Union. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed lenalidomide and bortezomib had been enrolled at the time of the data cutoff. The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, or ORR, duration of response, or DOR, progression-free survival, or PFS, overall survival, or OS, and cytogenetic analyses. Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent. At a median follow-up of 6.8 months with a median four cycles received, the median PFS and OS were 4.2 months and 11.9 months, respectively. The ORR was 35%, with 8% of patients achieving at least a very good partial response, or VGPR. The median DOR was 6.8 months. In patients refractory to prior lenalidomide or lenalidomide and bortezomib, similar PFS, OS, and ORR were achieved.
05:22 EDTCELGCelgene reports REVLIMID study data suggests improved response rates, PFS, OS
Subscribe for More Information
05:17 EDTCELGCelgene reports Vidaza Phase III study shows doubled overall survival times
Subscribe for More Information
December 8, 2014
16:00 EDTTSLA, AAPLOptions Update; December 8, 2014
Subscribe for More Information
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
13:21 EDTTSLATesla has an active bearish pattern, levels to watch
Subscribe for More Information
13:16 EDTAAPLApple trades off session lows, levels to watch
Subscribe for More Information
11:22 EDTTSLATesla estimated to sell 1,200 Model S in U.S. in November, InsideEVs says
Subscribe for More Information
09:22 EDTTSLATesla weakness a buying opportunity, says RW Baird
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
07:06 EDTMTGMGIC Investment reports November primary new insurance written $2.9B
Subscribe for More Information
06:37 EDTAAPLApple rumored to be launching 4-inch iPhone in 2015, Times of India reports
Apple is rumored to be developing a new iPhone with a 4-inch display, The Times of India reports, citing a report from The Electronic Times of Taiwan. According to supply chain sources, the device will launch in 2H15. Reference Link
06:22 EDTAAPLApple price target raised to $135 from $120 at Citigroup
Citigroup raised its earnings estimates for Apple after its field work indicated consumers are increasingly buying the higher memory iPhone 6 and 6+. Citi expects purchasing trends towards higher memory devices to drive stronger sales and margins. It believes consensus estimates are yet to factor in this development. The firm raised its price target for Apple shares to $135 from $120 and keeps a Buy rating on the name. Shares of phone maker closed Friday down 49c to $115.
06:15 EDTAAPLLenovo shipments expected to lead Samsung by 9M in 2015, DigiTimes reports
Lenovo (LNVGY) is estimated to beat Samsung (SSNLF) in mobile device shipments in 2015 by about 9M units, reports DigiTimes Research. Lenovo is set to beat Samsung by about 1M units in 2014 and become the second largest mobile computing device brand vendor worldwide behind Apple (AAPL). DigiTimes Research says Lenovo and Samsung plan to focus on maintaining tablet shipments as demand weakens in 2015. Reference Link
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use